A novel of synthetic iridoid glycoside, Picroside II inhibits temozolomide resistance proliferation by upregulating DHRS2 in glioblastoma

Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by pronounced cellular heterogeneity that contributes to chemoresistance and frequent recurrence. Resistance to temozolomide (TMZ) remains a major therapeutic challenge, highlighting the urgent need for alternative treatment strategies. Picroside II (PII), a natural iridoid glycoside, has demonstrated anticancer activity; however, its effects on TMZ-resistant GBM and the underlying molecular mechanisms remain largely unexplored. TMZ-resistant GBM cell lines were established by intermittently exposing parental GBM cells to gradually increasing concentrations of TMZ over a six-month period. The antitumor effects of PII were evaluated in vitro using assays for cell proliferation, migration, invasion, colony formation, cell cycle distribution, and apoptosis. Expression levels of apoptosis- and cell cycle–related proteins were analyzed by Western blotting. Transcriptomic alterations induced by PII were identified using next-generation sequencing (NGS). The therapeutic efficacy of PII alone or combined with TMZ was further examined in vivo using a xenograft mouse model. PII significantly inhibited cell proliferation, migration, invasion, and clonogenic capacity in TMZ-resistant GBM cells. PII treatment induced dose-dependent cell cycle arrest, characterized by an accumulation of cells in the G1 phase and a corresponding reduction in the G2/M phase population. Moreover, PII triggered intrinsic mitochondrial apoptosis, accompanied by dose-dependent modulation of key apoptosis- and cell cycle–regulatory proteins. NGS analysis revealed a marked upregulation of dehydrogenase/reductase 2 (DHRS2) following PII treatment. Consistent with in vitro findings, PII effectively suppressed tumor growth and enhanced DHRS2 expression in xenograft tumor tissues. PII exerts potent antitumor effects against TMZ-resistant GBM by inducing cell cycle arrest and mitochondrial apoptosis, potentially through the upregulation of DHRS2. These findings support PII as a, promising therapeutic candidate for overcoming TMZ resistance in GBM.

Authors

Institutions

Publication Details

Journal
Cell Death Discovery
Published
2026-11-21
DOI
https://doi.org/10.1038/s41420-026-03453-9
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A novel of synthetic iridoid glycoside, Picroside II inhibits temozolomide resistance proliferation by upregulating DHRS2 in glioblastoma

Tai‐Hsin Tsai, Yi‐Chiang Hsu, Cheng-Yu Tsai, YU-FENG SU et al.
Cell Death Discovery
Glioma Diagnosis and Treatment
article

A novel of synthetic iridoid glycoside, Picroside II inhibits temozolomide resistance proliferation by upregulating DHRS2 in glioblastoma

Tai‐Hsin Tsai, Yi‐Chiang Hsu, Cheng-Yu Tsai, YU-FENG SU, Kuan-Ting Lee
article en

Abstract

Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by pronounced cellular heterogeneity that contributes to chemoresistance and frequent recurrence. Resistance to temozolomide (TMZ) remains a major therapeutic challenge, highlighting the urgent need for alternative treatment strategies. Picroside II (PII), a natural iridoid glycoside, has demonstrated anticancer activity; however, its effects on TMZ-resistant GBM and the underlying molecular mechanisms remain largely unexplored. TMZ-resistant GBM cell lines were established by intermittently exposing parental GBM cells to gradually increasing concentrations of TMZ over a six-month period. The antitumor effects of PII were evaluated in vitro using assays for cell proliferation, migration, invasion, colony formation, cell cycle distribution, and apoptosis. Expression levels of apoptosis- and cell cycle–related proteins were analyzed by Western blotting. Transcriptomic alterations induced by PII were identified using next-generation sequencing (NGS). The therapeutic efficacy of PII alone or combined with TMZ was further examined in vivo using a xenograft mouse model. PII significantly inhibited cell proliferation, migration, invasion, and clonogenic capacity in TMZ-resistant GBM cells. PII treatment induced dose-dependent cell cycle arrest, characterized by an accumulation of cells in the G1 phase and a corresponding reduction in the G2/M phase population. Moreover, PII triggered intrinsic mitochondrial apoptosis, accompanied by dose-dependent modulation of key apoptosis- and cell cycle–regulatory proteins. NGS analysis revealed a marked upregulation of dehydrogenase/reductase 2 (DHRS2) following PII treatment. Consistent with in vitro findings, PII effectively suppressed tumor growth and enhanced DHRS2 expression in xenograft tumor tissues. PII exerts potent antitumor effects against TMZ-resistant GBM by inducing cell cycle arrest and mitochondrial apoptosis, potentially through the upregulation of DHRS2. These findings support PII as a, promising therapeutic candidate for overcoming TMZ resistance in GBM.

Cell Death Discovery
Kaohsiung Medical University (TW), Kaohsiung Medical University Chung-Ho Memorial Hospital (TW), Kaohsiung Municipal Hsiao-Kang Hospital (TW), I-Shou University (TW)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon